ASH 2022 | Driver mutations in MPNs and their impact on prognosis: JAK2, MPL, and CALR
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the key mutations associated with myeloproliferative neoplasms (MPNs) and how these impact prognosis. Overall, there are three key mutations identified in most patients with MPNs: JAK2, MPL and CALR. However, Dr Bose also explains that some patients also present with other mutations, including DMT3A, AXSL1 and splicing mutations, and are described as triple negatives. To conclude, Dr Bose goes on to discuss how these various mutations impact disease progression and prognosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; Morphosys: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Sierra Oncology: Honoraria; Karyopharm: Honoraria; Ionis: Research Funding; Incyte: Honoraria, Research Funding; CTI BioPharma: Honoraria, Research Funding; PharmaEssentia: Honoraria; Cogent: Honoraria, Research Funding; Blueprint: Honoraria, Research Funding; BMS: Honoraria, Research Funding; AbbVie: Honoraria; Promedior: Research Funding.
